Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2440903
Max Phase: Preclinical
Molecular Formula: C43H57F3N12O9
Molecular Weight: 828.98
Molecule Type: Small molecule
Associated Items:
ID: ALA2440903
Max Phase: Preclinical
Molecular Formula: C43H57F3N12O9
Molecular Weight: 828.98
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: NCCC(=O)NCCNC(=O)CCC(=O)NCCNC(=O)/N=C(\N)NCCC[C@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(CNC(N)=O)cc1.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C41H56N12O7.C2HF3O2/c42-20-19-35(56)47-23-22-45-33(54)17-18-34(55)46-24-25-49-41(60)53-39(43)48-21-7-12-32(37(57)50-26-28-13-15-29(16-14-28)27-51-40(44)59)52-38(58)36(30-8-3-1-4-9-30)31-10-5-2-6-11-31;3-2(4,5)1(6)7/h1-6,8-11,13-16,32,36H,7,12,17-27,42H2,(H,45,54)(H,46,55)(H,47,56)(H,50,57)(H,52,58)(H3,44,51,59)(H4,43,48,49,53,60);(H,6,7)/t32-;/m0./s1
Standard InChI Key: FKLPZFXVYBYMIS-UCRKPPETSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 828.98 | Molecular Weight (Monoisotopic): 828.4395 | AlogP: -0.34 | #Rotatable Bonds: 24 |
Polar Surface Area: 306.15 | Molecular Species: BASE | HBA: 8 | HBD: 11 |
#RO5 Violations: 2 | HBA (Lipinski): 19 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.25 | CX Basic pKa: 9.50 | CX LogP: -2.38 | CX LogD: -5.71 |
Aromatic Rings: 3 | Heavy Atoms: 60 | QED Weighted: 0.03 | Np Likeness Score: -0.42 |
1. Keller M, Kaske M, Holzammer T, Bernhardt G, Buschauer A.. (2013) Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors., 21 (21): [PMID:24074877] [10.1016/j.bmc.2013.08.065] |
Source(1):